Carboplatin-associated ototoxicity in children with retinoblastoma

Ibrahim Qaddoumi, Johnnie K. Bass, Jianrong Wu, Catherine A. Billups, Amy W. Wozniak, Thomas E. Merchant, Barrett G. Haik, Matthew Wilson, Carlos Rodriguez-Galindo

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Purpose: Carboplatin-induced ototoxicity remains poorly defined but is of potential great consequence in children with retinoblastoma. We retrospectively assessed the incidence of ototoxicity and its risk factors in children with retinoblastoma who were treated with carboplatin. Patients and Methods: We reviewed the audiologic test results of 60 patients with retinoblastoma who received front-line treatment with systemic carboplatin and vincristine according to the St Jude RET-3 protocol (n = 23) or best clinical management (n = 37). Ototoxicity was evaluated by three different grading systems. Results: Twelve patients (20%) developed ototoxicity at some time after treatment initiation; however, ototoxicity resolved in two patients, and thus,10 patients (17%) had sustained hearing loss as documented at their most recent audiologic evaluation. Nine of these 10 patients had grade 3 or 4 ototoxicity, and nine patients were less than 6 months of age at the start of chemotherapy. Age at the start of chemotherapy was the only risk factor identified as a significant predictor of sustained hearing loss. Younger age was associated with an increased incidence of hearing loss. The different ototoxicity grading systems showed good overall agreement in the identification of patients with ototoxicity. Agreement was greatest between the Brock and Children's Cancer Group systems. Conclusion: We found that young patients with retinoblastoma who were treated with systemic carboplatin had a higher incidence of ototoxicity than previously reported. Younger patients (< 6 months of age at the start of treatment) were more likely to have ototoxicity than were older patients. Children treated with carboplatin should routinely undergo thorough, long-term audiologic monitoring.

Original languageEnglish (US)
Pages (from-to)1034-1041
Number of pages8
JournalJournal of Clinical Oncology
Volume30
Issue number10
DOIs
StatePublished - Apr 1 2012

Fingerprint

Retinoblastoma
Carboplatin
Hearing Loss
Incidence
Drug Therapy
Vincristine
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Qaddoumi, I., Bass, J. K., Wu, J., Billups, C. A., Wozniak, A. W., Merchant, T. E., ... Rodriguez-Galindo, C. (2012). Carboplatin-associated ototoxicity in children with retinoblastoma. Journal of Clinical Oncology, 30(10), 1034-1041. https://doi.org/10.1200/JCO.2011.36.9744

Carboplatin-associated ototoxicity in children with retinoblastoma. / Qaddoumi, Ibrahim; Bass, Johnnie K.; Wu, Jianrong; Billups, Catherine A.; Wozniak, Amy W.; Merchant, Thomas E.; Haik, Barrett G.; Wilson, Matthew; Rodriguez-Galindo, Carlos.

In: Journal of Clinical Oncology, Vol. 30, No. 10, 01.04.2012, p. 1034-1041.

Research output: Contribution to journalArticle

Qaddoumi, I, Bass, JK, Wu, J, Billups, CA, Wozniak, AW, Merchant, TE, Haik, BG, Wilson, M & Rodriguez-Galindo, C 2012, 'Carboplatin-associated ototoxicity in children with retinoblastoma', Journal of Clinical Oncology, vol. 30, no. 10, pp. 1034-1041. https://doi.org/10.1200/JCO.2011.36.9744
Qaddoumi I, Bass JK, Wu J, Billups CA, Wozniak AW, Merchant TE et al. Carboplatin-associated ototoxicity in children with retinoblastoma. Journal of Clinical Oncology. 2012 Apr 1;30(10):1034-1041. https://doi.org/10.1200/JCO.2011.36.9744
Qaddoumi, Ibrahim ; Bass, Johnnie K. ; Wu, Jianrong ; Billups, Catherine A. ; Wozniak, Amy W. ; Merchant, Thomas E. ; Haik, Barrett G. ; Wilson, Matthew ; Rodriguez-Galindo, Carlos. / Carboplatin-associated ototoxicity in children with retinoblastoma. In: Journal of Clinical Oncology. 2012 ; Vol. 30, No. 10. pp. 1034-1041.
@article{8c2c6079566541cc9c81307845496ba3,
title = "Carboplatin-associated ototoxicity in children with retinoblastoma",
abstract = "Purpose: Carboplatin-induced ototoxicity remains poorly defined but is of potential great consequence in children with retinoblastoma. We retrospectively assessed the incidence of ototoxicity and its risk factors in children with retinoblastoma who were treated with carboplatin. Patients and Methods: We reviewed the audiologic test results of 60 patients with retinoblastoma who received front-line treatment with systemic carboplatin and vincristine according to the St Jude RET-3 protocol (n = 23) or best clinical management (n = 37). Ototoxicity was evaluated by three different grading systems. Results: Twelve patients (20{\%}) developed ototoxicity at some time after treatment initiation; however, ototoxicity resolved in two patients, and thus,10 patients (17{\%}) had sustained hearing loss as documented at their most recent audiologic evaluation. Nine of these 10 patients had grade 3 or 4 ototoxicity, and nine patients were less than 6 months of age at the start of chemotherapy. Age at the start of chemotherapy was the only risk factor identified as a significant predictor of sustained hearing loss. Younger age was associated with an increased incidence of hearing loss. The different ototoxicity grading systems showed good overall agreement in the identification of patients with ototoxicity. Agreement was greatest between the Brock and Children's Cancer Group systems. Conclusion: We found that young patients with retinoblastoma who were treated with systemic carboplatin had a higher incidence of ototoxicity than previously reported. Younger patients (< 6 months of age at the start of treatment) were more likely to have ototoxicity than were older patients. Children treated with carboplatin should routinely undergo thorough, long-term audiologic monitoring.",
author = "Ibrahim Qaddoumi and Bass, {Johnnie K.} and Jianrong Wu and Billups, {Catherine A.} and Wozniak, {Amy W.} and Merchant, {Thomas E.} and Haik, {Barrett G.} and Matthew Wilson and Carlos Rodriguez-Galindo",
year = "2012",
month = "4",
day = "1",
doi = "10.1200/JCO.2011.36.9744",
language = "English (US)",
volume = "30",
pages = "1034--1041",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Carboplatin-associated ototoxicity in children with retinoblastoma

AU - Qaddoumi, Ibrahim

AU - Bass, Johnnie K.

AU - Wu, Jianrong

AU - Billups, Catherine A.

AU - Wozniak, Amy W.

AU - Merchant, Thomas E.

AU - Haik, Barrett G.

AU - Wilson, Matthew

AU - Rodriguez-Galindo, Carlos

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Purpose: Carboplatin-induced ototoxicity remains poorly defined but is of potential great consequence in children with retinoblastoma. We retrospectively assessed the incidence of ototoxicity and its risk factors in children with retinoblastoma who were treated with carboplatin. Patients and Methods: We reviewed the audiologic test results of 60 patients with retinoblastoma who received front-line treatment with systemic carboplatin and vincristine according to the St Jude RET-3 protocol (n = 23) or best clinical management (n = 37). Ototoxicity was evaluated by three different grading systems. Results: Twelve patients (20%) developed ototoxicity at some time after treatment initiation; however, ototoxicity resolved in two patients, and thus,10 patients (17%) had sustained hearing loss as documented at their most recent audiologic evaluation. Nine of these 10 patients had grade 3 or 4 ototoxicity, and nine patients were less than 6 months of age at the start of chemotherapy. Age at the start of chemotherapy was the only risk factor identified as a significant predictor of sustained hearing loss. Younger age was associated with an increased incidence of hearing loss. The different ototoxicity grading systems showed good overall agreement in the identification of patients with ototoxicity. Agreement was greatest between the Brock and Children's Cancer Group systems. Conclusion: We found that young patients with retinoblastoma who were treated with systemic carboplatin had a higher incidence of ototoxicity than previously reported. Younger patients (< 6 months of age at the start of treatment) were more likely to have ototoxicity than were older patients. Children treated with carboplatin should routinely undergo thorough, long-term audiologic monitoring.

AB - Purpose: Carboplatin-induced ototoxicity remains poorly defined but is of potential great consequence in children with retinoblastoma. We retrospectively assessed the incidence of ototoxicity and its risk factors in children with retinoblastoma who were treated with carboplatin. Patients and Methods: We reviewed the audiologic test results of 60 patients with retinoblastoma who received front-line treatment with systemic carboplatin and vincristine according to the St Jude RET-3 protocol (n = 23) or best clinical management (n = 37). Ototoxicity was evaluated by three different grading systems. Results: Twelve patients (20%) developed ototoxicity at some time after treatment initiation; however, ototoxicity resolved in two patients, and thus,10 patients (17%) had sustained hearing loss as documented at their most recent audiologic evaluation. Nine of these 10 patients had grade 3 or 4 ototoxicity, and nine patients were less than 6 months of age at the start of chemotherapy. Age at the start of chemotherapy was the only risk factor identified as a significant predictor of sustained hearing loss. Younger age was associated with an increased incidence of hearing loss. The different ototoxicity grading systems showed good overall agreement in the identification of patients with ototoxicity. Agreement was greatest between the Brock and Children's Cancer Group systems. Conclusion: We found that young patients with retinoblastoma who were treated with systemic carboplatin had a higher incidence of ototoxicity than previously reported. Younger patients (< 6 months of age at the start of treatment) were more likely to have ototoxicity than were older patients. Children treated with carboplatin should routinely undergo thorough, long-term audiologic monitoring.

UR - http://www.scopus.com/inward/record.url?scp=84859702888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859702888&partnerID=8YFLogxK

U2 - 10.1200/JCO.2011.36.9744

DO - 10.1200/JCO.2011.36.9744

M3 - Article

VL - 30

SP - 1034

EP - 1041

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -